The Supervision Committee of the Mercado Alternativo Bursátil (MAB) has announced the listing of Bioorganic Research and Services, S.A (Bionaturis) on the Growth Companies segment of this market, following a thorough review of all the information presented by the company and after the favourable assessment report on its listing issued by MAB’s Coordination and Admission Committee.
The company’s listing is scheduled to take place tomorrow, under the trading code BNT. Trading will be through a price setting mechanism which will match buy and sell orders by means of two daily auction periods or “fixings”, at 12 hrs and at 16 hrs.
KPMG is acting as Registered Adviser and Bankia Bolsa as Liquidity Provider and Underwriters.
Bionaturis is a biopharmaceutical company founded in Cádiz, in 2005, that develops and manufactures medicines for the biopharmaceuticals and veterinary sector. The company specializes in the prevention and treatment of niche diseases, among which are diseases regarded as rare. Bionaturis aims to rank among the top manufacturers of biopharmaceutical products for veterinary and human use.